Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates

References

• Bergami A., Fracasso C., Garattini S., Caccia S. Brain uptake and acute indole-depleting effect of dexfenfluramine in squirrel monkeys after a high-dose regimen. Pharmaceutical Sciences 1995; 1: 45–48
   Google Scholar
• Borroni E., Ceci A., Garattini S., Mennini T. Differences between D-fenfluramine and D-norfenfiuramine in serotonin presynaptic mechanisms. Journal of Neurochemistry 1983; 40: 891–893
   PubMed Web of Science ®Google Scholar
• Caccia S., Axelli M., Ferrarese A., Fracasso C., Garattini S. Single- and multiple-dose kinetics of D-fenfluramine in rats given anorectic and toxic doses. Xenobiotica 1992b; 22: 217–226
   PubMed Web of Science ®Google Scholar
• Caccia S., Anelli M., Ferrarese A., Fracasso C., Garattini S. The role of D-norfenfluramine in the indole-depleting effect of D-fenfluramine in the rat. European Journal of Pharmacology 1993a; 233: 71–77
   PubMedGoogle Scholar
• Caccia S., Anelli M., Fracasso C., Frittoli E., Giorcelli P., Gobbi M., Taddei C., Garattini S., Mennini T. Anorectic effect and brain concentrations of D-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on seretonergic mechanisms. Naunyn-Schmiedeberg's Archives of Pharmacology 1993b; 347: 306–312
   PubMed Web of Science ®Google Scholar
• Caccia S., Ballabio M., Guiso G., Rocchetti M., Garattini S. Species differences in the kinetics and metabolism of fenfluramine isomers. Archives Internationales de Pharmacodynamie et de Therapie 1982; 258: 15–28
   PubMedGoogle Scholar
• Caccia S., Sarati S., Anelli M., Garattini S. Effect of escalating doses of D-fenfluramine on the content of indoles in brain. Neuropharmacology 1992a; 31: 875–879
   PubMedGoogle Scholar
• Caldwell J. The metabolism of amphetamines in mammals. Drug Metabolism Reviews 1976; 5: 219–280
   PubMed Web of Science ®Google Scholar
• Campbell D. B., Richards R. P., Caccia S., Garattini S. Stereoselective metabolism and the fate of fenfluramine in animals and man. Development of Drugs and Modern Medicines, J. W. Gorrod, G. G. Gibson, M. Mitchard. Horwood, Chichester 1986; 298–331
   Google Scholar
• Fleisher M. R., Campbell D. B. Fenfluramine overdosage. Lancet 1969; ii: 1306–1307
   Google Scholar
• Garattini S., Bizzi A., Caccia S., Mennini T. Progress report on the anorectic effects of dexfenfluramine, fluoxetine and sertraline. International Journal of Obesity 1992; 16(Suppl. 3)S43–50
   PubMedGoogle Scholar
• Garattini S., Caccia S., Mennini T., Samanin R., Consolo S., Ladinsky H. Biochemical pharmacology of the anorectic drug fenfluramine: a review. Current Medical Research and Opinion 1979; 6(Suppl. 1)15–27
   Google Scholar
• Gibson E. L., Kennedy A. J., Curzon G. D-Fenfluramine and D-norfenfluramine-induced hypophagia: differential mechanisms and involvement of postsynaptic 5-HT receptors. European Journal of Pharmacology 1993; 242: 83–90
   PubMed Web of Science ®Google Scholar
• Johnson M. P., Nichols D. E. Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and nonfenfluramine. Pharmacology Biochemistry and Behaviour 1990; 36: 105–109
   PubMed Web of Science ®Google Scholar
• Kleven M. S., Selden L. S. D-, and DL-fenfluramine cause long-lasting depletions of serotonin in rat brain. Brain Research 1989; 505: 351–353
   PubMedGoogle Scholar
• Marchant N. C., Breen M. A., Wallace D., Bass S., Taylor A. R., Ings R. M. J., Campbell D. B., Williams J. Comparative biodisposition and metabolism of 14C-(β)- fenfluramine in mouse, rat, dog and man. Xenobiotica 1992; 22: 1251–1266
   PubMed Web of Science ®Google Scholar
• McCann U., Hatzidimitriou G., Ridenour A., Fisher C., Yuan J., Katz J., Ricaurte G. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. Journal of Pharmacology and Experimental Therapeutics 1994; 269: 792–798
   PubMed Web of Science ®Google Scholar
• Mennini T., Bizzi A., Caccia S., Codegoni A., Fracasso C., Frittoli E., Guiso G., Martin, Padura I., Taddei C., Uslenghi A., Garattini S. Comparative studies on the anorectic activity of D-fenfluramine in mice, rats, and guinea pigs. Naunyn-Schmiedeberg's Archives of Pharmacology 1991; 343: 483–490
   PubMed Web of Science ®Google Scholar
• Ricaute G. A., Molliver M. E., Martello M. B., Kats J. L., Wilson M. A., Martello A. L. Dexfenfluramine neurotoxicity in brains of non-human primates. Lancet 1991; 338: 1487–1488
   PubMedGoogle Scholar
• Schuster C. R., Lewis M., Seiden L. S. Fenfluramine: neurotoxicity. Psychopharmacology Bulletin 1986; 22: 148–151
   PubMedGoogle Scholar
• Silverstone T., Smith G., Richards S. A comparative evaluation of dexfenfluramine and DL-fenfluramine. Body Weight Control, The Physiology, Clinical Treatment and Prevention of Obesity, A. E. Bender, L. J. Brookes. Churchill Livingstone, edinburgh 1987; 240–246
   Google Scholar
• Smith R. L., Dring L. G. Patterns of metabolism of β-phenylisopropylamines in man and other species. Amphetamines and Related Compounds, E. Costa, S. Garattini. Raven, New York 1970; 121–139
   Google Scholar
• Zaczek R., Battaglia G., Culp S., Appel N. M., Contrera J. F., De Souza E. B. Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: pharmacokinetic, dose response, regional specificy and time course data. Journal of Pharmacology and Experimental Therapeutics 1990; 253: 104–112
   PubMed Web of Science ®Google Scholar